Other investigators showed that Mitotane-EDP might be more beneficial in patients with topoisomerase-2 alpha and excision repair cross-complementing group (ERCC1) mutations.27,28 This suggests that a biomarker-based treatment approach in ACC could be feasible. Here, ERCC1 is linked to adrenal cortex carcinoma.